Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States

Nightingale Health Plc

Press release

23 January 2025 at 11:00 a.m. (EET)

Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, today announces performance metrics of the latest generation of its disease risk assessments that will be rolled out in Singapore and United States as a part of its Health Check product line. The latest generation of the disease risk assessments have taken advantage of Nightingale Health’s growing and diverse global data resources and the latest machine learning techniques to provide the world leading disease risk analysis from just a blood sample, age and sex.  

Nightingale Health has compared area under the curve (AUC) values between Nightingale Health’s disease risk assessments and clinical risk assessments and other tools currently routinely used in healthcare. AUC is the metric used routinely in medicine to capture in a single number a test’s ability to effectively identify individuals at high risk of a disease across a whole population. AUC values range from 0.5 to 1.0, with 1.0 indicating perfect discrimination. The comparison of AUC metrics is presented in the table below:

Enabling preventative healthcare to solve the crisis of chronic diseases

The performance of Nightingale Health’s disease risk assessments is equal to or better than all the current routinely used clinical tools shown here. Crucially, however, Nightingale Health’s test requires only a single blood sample with age and sex as clinical parameters to consistently detect the risk of all the diseases presented in the table above, so that detecting the disease risks does not consume time and resources of the healthcare system.

In comparison, detecting all the disease risks in the table above with the current clinical tools would require tens of clinical parameters to be collected, e.g. questionnaires, interviews, measurements, and several blood tests, consuming substantial amounts of scarce healthcare resources. This means broad, holistic disease risk detection is virtually impossible, and the collected data inconsistent due to the subjective nature of some clinical data parameters.  

For the first time in healthcare, Nightingale Health enables high performance holistic disease risk detection that can be rolled out population wide. Efficient detection of disease risks is the only way to build preventative healthcare and solve the crisis of chronic diseases.

Introducing two new disease risk assessments to Health Check product line

When starting the production in Singapore and the US, Nightingale Health also introduces two new disease risk assessments available in the Health Check product line: fatty liver disease (MASLD) and stroke. MASLD is the most common early form of chronic liver disease, and it may exist without causing any symptoms. The incidence of MASLD is increasing rapidly and it is becoming the next major source of population wide disease burden. If untreated, MASLD can lead to more severe liver diseases, such as liver fibrosis, cirrhosis or even liver cancer.

Introducing modular architecture for clinical workflow integration and localization

In addition to introducing new disease risks, the architecture of the latest generation disease risk assessments allows the risk assessments to also incorporate additional clinical parameters. This flexibility of Nightingale Health’s risk assessment architecture allows an easy integration with any routine clinical workflows as the currently collected clinical parameters can be used to enhance the disease risk assessments.

The enhanced architecture also enables Nightingale Health to localize its disease risk assessment to different countries and regions around the world. The sophisticated modular architecture tailors absolute risk predictions to the disease incidence rates for each country and ethnic group, making Nightingale Health’s risk assessment fully compatible with the standard localization protocol used in existing clinical tools. Localization for the main ethnic groups in Singapore is already completed, and the US localization will be finalised in the first quarter of 2025.   

“The volume of data behind Nightingale Health’s risk assessments is on a totally new scale, which has enabled us to outperform five out of seven disease risk assessments currently used. With this breakthrough performance data and the experience of successfully completing all required regulatory processes in multiple countries, we are ready to bring this technology available worldwide” says Jeffrey Barrett, Nightingale Health’s Chief Scientific Officer.

“The ability to detect disease risks is the foundation of preventative healthcare. The proven performance of Nightingale Health’s risk assessments together with the exceptionally simple implementation makes it possible to roll out the technology in nationwide preventative healthcare settings everywhere in the world and enable a better way of doing healthcare” says Teemu Suna, CEO and Founder of Nightingale Health.                                                                                                                             

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/

Tags: